Leadership

Our team of passionate biopharmaceutical leaders combines deep expertise in drug development and commercialization
Meet our leadership teamLatest news
View more news > September 20, 2023
Read press release
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 18, 2023
Read press release
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rare perspective
Insights and information on our approach to collaborating with rare disease communities, supporting our teammates at Ultragenyx, and developing new therapies for rare disease
Read our blog >